Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Humanwell Healthcare Group Co Ltd (Humanwell Healthcare) is a pharmaceutical company that focuses on the pharmaceutical industry, focusing on the production and internationalization of pharmaceutical preparations. It offers products that include narcotic drugs, steroid hormones drugs, and Uyghur medicine. Humanwell Healthcare's product portfolio includes anesthetics (post-surgery), fertility regulation drugs; CNS medicines including sedative and sedation awaken drugs, anti-be chic and anti-epilepsy drugs; OTC drugs targeting digestive disorders, cold and flu, anti-inflammation, anti-infection and nutritional supplements; anti-infective drugs; and herbal medicines. The company offers its products in the dosage forms of injectables, capsules, oral liquids, syrup and granules. Humanwell Healthcare is headquartered in Wuhan, Hubei, China.
Headquarters
China
Address
No. 666 Gaoxin Avenue, Donghu High-Tech District, Wuhan, Hubei, 430075
Website
www.humanwell.com.cn
Telephone
86 27 87597232
No of Employees
17,153
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
600079 (SHA)
Revenue (2024)
$3.3B
-5.8%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
39.5%
(2024 vs 2023)
Market Cap*
$4.2B
Net Profit Margin (2024)
XYZ
48.0%
(2024 vs 2023)
* As of and is in US$
Humanwell Healthcare Group Co Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Anesthetics | RuiMa |
| Fertility Regulation Drugs | LinBingFen |
| Herbal Medicines | Guang Shi Tong |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Regulatory Approval | In December, Wuhan Jiulong Pharmaceutical Co., Ltd. received approval from NMPA for the marketing of its Class 4 generic ibuprofen suspension. |
| 2025 | New Products/Services | In September, the company launched P2X purinoceptor 7 (P2RX7; P2X7) antagonists. |
| 2025 | New Products/Services | In February, the company developed new proteolysis targeting chimera (PROTAC) compounds targeting interleukin-1 receptor-associated kinase 4 (IRAK-4). |
Competitor Comparison
| Key Parameters | Humanwell Healthcare Group Co Ltd | Huadong Medicine Co Ltd | Shanghai Fosun Pharmaceutical (Group) Co Ltd | Jinyao Pharmaceutical Co Ltd | Guilin Sanjin Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Wuhan | Hangzhou | Shanghai | Tianjin | Guilin |
| State/Province | Hubei | Zhejiang | Shanghai | Tianjin | Guangxi |
| No. of Employees | 17,153 | 18,265 | 40,603 | 2,884 | 2,556 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Deng Weidong | Chairman | Executive Board | 2025 | 59 |
| Du Wentao | Chief Financial Officer; General Manager | Senior Management | 2025 | 59 |
| Yin Qiang | Deputy General Manager | Senior Management | 2020 | 45 |
| Li Jun | Deputy General Manager | Senior Management | 2025 | 49 |
| Liu Nanhong | Deputy General Manager; Secretary | Senior Management | 2025 | 48 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer